Long-Term Outcome of Patients (Pts) with Her2-Positive (Her2+) Metastatic Breast Cancer (Mbc) Who Achieved a Complete Response (Cr) After Antiher2 Therapy (Her2Tx)
نویسندگان
چکیده
منابع مشابه
Long Term Trastuzumab in Metastatic Setting of the Patients with HER2 Positive Breast Cancer
Approximately 20% of breast cancer tumours show overexpression of human epidermal growth factor receptor 2 (HER2) protein, and HER2 overexpression has been frequently identified as a factor indicating poor prognosis [1,2]. Trastuzumab is a humanized monoclonal antibody that targets the extracellular domain of the HER2 protein. The antitumor functions of trastuzumab are associated with its abili...
متن کاملResponses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer.
BACKGROUND Women with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) can respond to multiple lines of anti-HER2 therapy. It is unknown whether these patients will derive further clinical benefit following treatment with trastuzumab-MCC-DM1 (T-DM1). PATIENTS AND METHODS We retrospectively identified HER2-positive MBC patients treated with T-DM1 and char...
متن کاملDuration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
PURPOSE The duration of anti-HER2 blockage therapy in metastatic breast cancer patients is still unclear. We aimed to evaluate the effect of the anti-HER2 blockage therapy duration and other factors on survival in HER2 positive metastatic breast carcinoma (MBC) patients. METHODS The medical records of 193 HER2 positive MBC patients, who did not have the opportunity to receive adjuvant trastuz...
متن کاملHER2-directed therapy for metastatic breast cancer.
Human epidermal growth factor receptor 2 (HER2) overexpression drives the biology of 20% of breast cancers, and predicts a poor prognosis for patients. HER2-targeted therapies significantly improve outcomes for HER2-positive patients with both early and metastatic breast cancer. Currently three HER2-targeted agents, trastuzumab (Herceptin), lapatinib (Tykerb), and pertuzumab (Perjeta), are avai...
متن کاملProlonged survival of patients receiving trastuzumab beyond disease progression for HER2 overexpressing metastatic breast cancer (MBC).
BACKGROUND The aim of this retrospective analysis was to evaluate the impact of trastuzumab-based regimens on the survival of patients with HER2-overexpressing metastatic breast cancer (MBC). The study specifically focussed on the influence of the continuation of trastuzumab-based treatment despite tumor progression on survival. PATIENTS AND METHODS Patients with HER2 overexpressing MBC were ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 2014
ISSN: 0923-7534
DOI: 10.1093/annonc/mdu329.25